# A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

> **NCT06681870** · PHASE1 · WITHDRAWN · sponsor: **Astellas Pharma Global Development, Inc.**

## Conditions studied

- CLDN6-positive Solid Tumor
- Ovarian Cancer
- Endometrial Cancer
- Non-small Cell Lung Cancer
- Testicular Cancer
- Metastatic or Locally Advanced Solid Tumor Cancer

## Interventions

- **DRUG:** ASP1893

## Key facts

- **NCT ID:** NCT06681870
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-31
- **Primary completion:** 2029-03-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** A business decision was made to not initiate this study.
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06681870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06681870, "A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06681870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*